Filtered By:
Specialty: Drugs & Pharmacology
Condition: Bleeding

This page shows you your search results in order of date. This is page number 15.

Order by Relevance | Date

Total 688 results found since Jan 2013.

Fatal adverse events of rivaroxaban combined with aspirin: an analysis using data from VigiBase
ConclusionsFatal AEs related to rivaroxaban combined with aspirin, including bleeding and ischemic events, have been reported mostly in the elderly, and sometimes involved medication errors. The fatal AEs mainly manifested as serious bleeding, and most of them occurred in patients with concurrent multiple risk factors. Monitoring coagulation during rivaroxaban treatment is recommended in very high-risk ASCVD populations, and attention should be paid to prevention of medication errors.
Source: European Journal of Clinical Pharmacology - July 1, 2022 Category: Drugs & Pharmacology Source Type: research

XaMINA: A Real-World, Prospective, Observational Study of Treatment-Na ïve Patients Treated with Rivaroxaban for Stroke Prevention in Atrial Fibrillation in Asia
ConclusionXaMINA demonstrated low incidence rates of major bleeding events and thromboembolic events in patients with NVAF newly initiating rivaroxaban in South Korea and Taiwan, consistent with previous real-world studies reconfirming the results of the ROCKET AF study.Trial RegistrationThe trial was registered on ClinicalTrials.gov (identifier NCT03284762) on 15 September 2017.
Source: Advances in Therapy - June 30, 2022 Category: Drugs & Pharmacology Source Type: research

Danhong injection combined with tPA protects the BBB through Notch-VEGF signaling pathway on long-term outcomes of thrombolytic therapy
In this study, the rats were randomly divided into sham group, vehicle group, DHI group (4 mL/kg), tPA group (5 mg/kg) and DHI+tPA group (4 mL/kg+ 2.5 mg/kg), administered intravenously 4.5 h since focal embolic stroke modeling. After 3 days and 7 days of cerebral ischemia, the neurological function of each treatment group was significantly improved compared with the vehicle group. The combination of DHI and tPA significantly reduced Evans blue (EB) penetration as well as the expressions of the proteins MMP-9, PAI-1 and P-selectin, while upregulating the expressions of claudin-5, occludin, and ZO-1 mRNA. Furthermore, the e...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - June 19, 2022 Category: Drugs & Pharmacology Authors: Simiao Chen Jinghui Zhang Min Li Jing Zhou Yuyan Zhang Source Type: research

Comparative effectiveness and safety of different combinations of antithrombotic regimens in atrial fibrillation patients with stent insertions
This study aims to compare the risks of major adverse cardiac events (MACEs), including cardiovascular death, myocardial infarction, ischemic stroke and transient ischemic attack, and major bleeding across different antithrombotic regimens in Asian atrial fibrillation (AF) patients with stent insertions. We conducted a retrospective cohort study using Taiwan's National Health Insurance Research Database and National Mortality Registry. A total of 10,208 nonvalvular AF patients who had undergone percutaneous coronary intervention (PCI) with stents for the first time in 2007-2017 were identified. Most patients (68.4%) were p...
Source: Clinical Pharmacology and Therapeutics - June 9, 2022 Category: Drugs & Pharmacology Authors: Han-Hsin Chueh Shih-Tsung Huang Shang-Hung Chang Shin-Yi Lin Fei-Yuan Hsiao Source Type: research

Comparison of aspirin and P2Y12 inhibitors for secondary prevention of ischaemic stroke: A systematic review and meta-analysis
CONCLUSION: This meta-analysis suggests that P2Y12 inhibitors are more effective than aspirin in preventing recurrent ischaemic stroke among ischaemic stroke patients despite the absence of any effect on a new ischaemic or haemorrhagic stroke, a new clinical vascular event, all-cause death, and major or minor bleeding events.PMID:35619249 | DOI:10.2174/2772432817666220526162144
Source: Pharmacological Reviews - May 27, 2022 Category: Drugs & Pharmacology Authors: Kaili Zhang Yongle Wang Tingting Liu Xiaoyuan Niu Source Type: research

Use of oral anticoagulants among individuals with cancer and atrial fibrillation in the United States, 2010 –2016
ConclusionsNearly 7 out of 10 patients with cancer and NVAF did not receive anticoagulation. Use of DOACs increased from 2010 to 2016, with a corresponding decline in warfarin use. DOACs are used less than warfarin among those at higher risk of stroke.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 6, 2022 Category: Drugs & Pharmacology Authors: Shirin Ardeshirrouhanifard, Huijun An, Ravi K. Goyal, Mukaila A. Raji, Jodi B. Segal, G. Caleb Alexander, Hemalkumar B. Mehta Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

Investigational drugs for ischemic stroke: what's in the clinical development pipeline for acute phase and prevention?
Expert Opin Investig Drugs. 2022 Apr 29. doi: 10.1080/13543784.2022.2072725. Online ahead of print.ABSTRACTINTRODUCTION: Stroke is a leading cause of disability and mortality and its burden expected to increase. The only approved drug for acute ischemic stroke is the intravenous thrombolytic alteplase. The risk of bleeding complications is one of the reasons for the undertreatment of eligible patients. Numerous drugs are currently being developed to improve safety-efficacy.AREAS COVERED: We reviewed literature from January 1st, 2000, to 15th January 2022 for the development and testing of novel drugs with the aim of target...
Source: Expert Opinion on Investigational Drugs - April 29, 2022 Category: Drugs & Pharmacology Authors: Maria Giulia Mosconi Maurizio Paciaroni Walter Ageno Source Type: research